Browsing Tag
Actinic keratosis
3 posts
Will pharmacokinetics data support 240 cm2 treatment fields for Ameluz?
Biofrontera Inc. advances Ameluz toward 240 cm2 FDA review. Explore the regulatory, financial, and competitive stakes in dermatology markets.
Is photodynamic therapy ready to move beyond facial use in actinic keratosis care?
Biofrontera Inc.’s Phase 3 Ameluz data extend photodynamic therapy beyond the face. Find out how this could reshape field treatment decisions.
Torqur AG reports promising Phase 2 results for bimiralisib, full data expected by June
Torqur AG, a biotechnology company specializing in oncology and dermatology treatments, has presented interim Phase 2 clinical trial…